185910-12-7

Basic information

• Product Name: 1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI)
• Synonyms: 1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI);1,4,5-Trimethylimidazole-2-carboxaldehyde;1,4,5-trimethyl-1H-imidazole-2-carbaldehyde(SALTDATA: FREE);1,4,5-trimethyl-2-imidazolecarboxaldehyde;1,4,5-trimethylimidazole-2-carbaldehyde
• CAS NO: 185910-12-7
• Molecular Formula: C₇H₁₀N₂O
• Molecular Weight: 138.169
• Product Categories: AMINETERTIARY
• Mol File: 185910-12-7.mol

Chemical Properties

• Boiling Point: 289℃
• Flash Point: 128℃
• Appearance: /
• Density: 1.09
• Vapor Pressure: 0.00232mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI)(185910-12-7)
• EPA Substance Registry System: 1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI)(185910-12-7)

Safety Data

• Hazardous Substances Data: 185910-12-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI) is used as a building block for the synthesis of more complex molecules. Its unique structure and properties make it a valuable component in various chemical reactions, contributing to the development of new compounds with potential applications in different industries.
Used in Pharmaceutical Industry:
1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI) is used as a key intermediate in the synthesis of pharmaceutical compounds. Its presence in the molecular structure can influence the biological activity and therapeutic properties of the final drug product, making it an essential component in the development of new medications.
Used in Research and Development:
1H-Imidazole-2-carboxaldehyde,1,4,5-trimethyl-(9CI) is used as a research compound in academic and industrial laboratories. Its unique chemical properties and potential reactivity with other molecules make it an interesting subject for studies aimed at understanding its behavior and exploring its potential applications in various fields.

InChI:InChI=1/C7H10N2O/c1-5-6(2)9(3)7(4-10)8-5/h4H,1-3H3

Upstream product

• 20185-22-2 1,4,5-Trimethylimidazole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1207454-70-3 ethyl 2-(4-fluorophenyl)-4-oxo-3-(1,4,5-trimethyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 185910-13-8 (1,4,5-Trimethyl-1H-imidazol-2-yl)-methanol 

Relevant articles and documents

Asymmetric Copper(II)-catalysed nitroaldol (Henry) reactions utilizing a chiral C1-symmetric dinitrogen ligand

A series of stable chiral C1-symmetric dinitrogen ligands were conveniently synthesized in high yields by condensation of chiral amines [(-)-exo-bornylamine or (+)-(1S,2S,5R)-menthylamine] with various substituted imidazolecarbaldehydes. With the assistance of base, the ligand L1 in combination with CuCl2·2H2O (2.5 mol-% or 5.0 mol-%) can efficiently promote nitroaldol (Henry) reactions between a variety of aldehydes and nitromethane. Both aromatic and aliphatic aldehydes were tolerated in our catalytic system, affording the expected nitroalcohol products in high yields (up to 97%) and with good enantioselectivities (up to 96%) under mild reaction conditions. A series of chiral C1-symmetric dinitrogen ligands were conveniently synthesized in high yields by condensations of chiralamines with various substituted imidazolecarbaldehydes. The ligand L1 in conjunction with CuCl2·2H2O can efficiently promote nitroaldol (Henry) reactions between various aldehydes and nitromethane in high yields (up to 97%) and with good enantioselectivities (up to 96%).

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

A direct synthetic approach to novel quadrupolar [14]azolophanes

A convergent '3+1' synthesis allowed a simple entrance to the first examples of [14]metaazolophanes 1 and [14l(meta-ortho)2azolophanes 2 built up from heterocyclic betaine subunits, illustrating a prototype of phanes constructed by both highly π-excessiveand highly π-deficient heteroaromatic moieties linked in a 1,3-alternating fashion.